Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Post by Keminor74on May 20, 2020 2:10pm
153 Views
Post# 31052379

Good news available financing COVID-19

Good news available financing COVID-19

https://www.lapresse.ca/covid-19/202005/20/01-5274276-des-dizaines-de-millions-en-financement-aux-grandes-entreprises.php


"There is no maximum per se, since each request will be assessed on a case-by-case basis, according to the company's cash flow needs for the next year, said the finance minister on Wednesday morning.
 
However, it is not yet clear when Canadian businesses will be able to receive federal funding. The money will be distributed "as soon as possible," said Minister Morneau.
 
 
Businesses will have to reimburse the state, the finance minister said. The loan is for five years and is repayable at any time. One fifth of the loan is considered a priority claim, while the rest is unsecured.
 
<< Previous
Bullboard Posts
Next >>